Kim, Yong Bae
Byun, Hwa Kyung
Wee, Chan Woo
Kim, Hojin
Kim, Seyoung
Yang, Gowoon
Kim, Jina
Park, Sang Joon
Lee, Jung-Yun
Funding for this research was provided by:
the National R&D Program for Cancer Control through the National Cancer Center(NCC) funded by the Ministry of Health & Welfare, Republic of Korea (HA22C0021, HA22C0021, HA22C0021, HA22C0021, HA22C0021, HA22C0021)
Article History
Received: 21 July 2023
Accepted: 15 September 2023
First Online: 20 October 2023
Declarations
:
: No potential conflict of interest relevant to this article was reported.
: Protocol of the SABR-ROC trial was approved by Institutional Review Board of Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea (4-2022-0286) on April 7th, 2022, Scientific Review Board of KGOG (3064) on April 25th, 2022, and Protocol Review Board of KROG (2204) on July 12th, 2022. All clinical treatments are conducted in accordance to International Good Clinical Practice Guidelines and the Declaration of Helsinki. Written Informed consent is obtained from each participant before enrollment. Participants are aware of the purpose, potential advantages, and risks of the trial.
: Not applicable.